Black Hairy Tongue After Immune Checkpoint Inhibitors in NSCLC: A Case Report and Review of the Literature
- 26 March 2021
- journal article
- review article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 22 (6), e804-e807
- https://doi.org/10.1016/j.cllc.2021.03.008
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceutical Company
- AstraZeneca
- Roche
- Bristol-Myers Squibb
- Pfizer
- Boehringer Ingelheim
This publication has 13 references indexed in Scilit:
- Immune-Related Oral, Otologic, and Ocular Adverse EventsPublished by Springer Science and Business Media LLC ,2020
- Oral manifestations in patients with diabetes mellitusWorld Journal of Diabetes, 2019
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysisZeitschrift für Krebsforschung und Klinische Onkologie, 2018
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and NailsAmerican Journal of Clinical Dermatology, 2018
- Black Hairy Tongue: Predisposing Factors, Diagnosis, and TreatmentAmerican Journal of Clinical Dermatology, 2017
- Atypical autoimmune adverse effects with checkpoint blockade therapiesAnnals of Oncology, 2017
- Oral health in oncology: impact of immunotherapySupportive Care in Cancer, 2014
- Black hairy tongue syndromeWorld Journal of Gastroenterology, 2014
- Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung CancerAnnals of Dermatology, 2011
- Drug‐Induced Black Hairy TonguePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010